Huntington National Bank Sells 34,789 Shares of Haleon plc (NYSE:HLN)

Huntington National Bank decreased its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 89.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,295 shares of the company's stock after selling 34,789 shares during the period. Huntington National Bank's holdings in Haleon were worth $41,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Procyon Advisors LLC increased its holdings in shares of Haleon by 41.3% in the 4th quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock worth $2,196,000 after buying an additional 67,329 shares during the last quarter. HighTower Advisors LLC grew its position in Haleon by 27.2% in the third quarter. HighTower Advisors LLC now owns 350,795 shares of the company's stock worth $3,701,000 after acquiring an additional 74,970 shares in the last quarter. Jane Street Group LLC increased its stake in Haleon by 1,689.4% in the third quarter. Jane Street Group LLC now owns 264,977 shares of the company's stock valued at $2,803,000 after acquiring an additional 250,169 shares during the last quarter. Bank of New York Mellon Corp raised its position in Haleon by 29.8% during the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after purchasing an additional 475,934 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company's stock worth $53,791,000 after purchasing an additional 1,026,939 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Trading Up 4.3 %

Shares of NYSE:HLN traded up $0.42 during trading on Friday, reaching $10.05. 16,215,293 shares of the company traded hands, compared to its average volume of 6,973,866. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 52-week low of $7.99 and a 52-week high of $10.80. The firm has a market capitalization of $45.38 billion, a price-to-earnings ratio of 29.54, a P/E/G ratio of 2.82 and a beta of 0.24. The business's fifty day moving average is $10.04 and its 200-day moving average is $9.82.

Haleon (NYSE:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion during the quarter, compared to analysts' expectations of $3.38 billion. As a group, analysts forecast that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently declared a -- dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is currently 58.97%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley downgraded shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a report on Monday, March 3rd. Finally, Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Six research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.